LRCX vs. BBIO
LRCX (Lam Research Corporation) and BBIO (BridgeBio Pharma, Inc.) are both stocks. LRCX operates in Semiconductor Equipment & Materials (Technology), while BBIO operates in Biotechnology (Healthcare). Over the past 5 years, LRCX returned 37.09%/yr vs 8.42%/yr for BBIO. Their 0.28 correlation means their historical movements had little consistent relationship.
Performance
LRCX vs. BBIO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, LRCX achieves a 71.50% return, which is significantly higher than BBIO's 4.71% return.
LRCX
- 1D
- -1.58%
- 1M
- -25.11%
- 6M
- 25.75%
- YTD
- 71.50%
- 1Y
- 210.67%
- 3Y*
- 61.40%
- 5Y*
- 37.09%
- 10Y*
- 43.64%
- ALL TIME*
- 23.67%
BBIO
- 1D
- -2.50%
- 1M
- 7.47%
- 6M
- 3.65%
- YTD
- 4.71%
- 1Y
- 69.43%
- 3Y*
- 32.71%
- 5Y*
- 8.42%
- 10Y*
- —
- ALL TIME*
- 14.52%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $163.36M | $283.28M | $252.33M | |
| $3.65B | $3.82B | $3.92B |
LRCX vs. BBIO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
LRCX Lam Research Corporation | 71.50% | 139.16% | -6.84% | 88.63% | -40.72% | 53.66% | 64.18% | 62.81% |
BBIO BridgeBio Pharma, Inc. | 4.71% | 178.75% | -32.03% | 429.79% | -54.32% | -76.54% | 102.88% | 14.51% |
Correlation
The correlation between LRCX and BBIO is 0.29, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.29 |
Correlation (3Y) Balances recent behavior with more history. | 0.27 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.30 |
Correlation (All Time) Calculated using the full available price history since Jun 27, 2019 | 0.28 |
Fundamentals
LRCX:
$366.44B
BBIO:
$15.69B
LRCX:
$5.75
BBIO:
-$3.74
LRCX:
15.93
BBIO:
27.48
LRCX:
$23.23B
BBIO:
$566.04M
LRCX:
$11.73B
BBIO:
$538.20M
LRCX:
$8.70B
BBIO:
-$602.24M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
LRCX vs. BBIO — Risk / Return Rank
LRCX
BBIO
LRCX vs. BBIO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Lam Research Corporation (LRCX) and BridgeBio Pharma, Inc. (BBIO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| LRCX | BBIO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.93 | ||
| Sortino ratioReturn per unit of downside risk | +1.18 | ||
| Omega ratioGain probability vs. loss probability | 1.42 | 1.28 | +0.13 |
| Calmar ratioReturn relative to maximum drawdown | 5.08 | 3.45 | +1.63 |
| Martin ratioReturn relative to average drawdown | 21.44 | 7.74 | +13.70 |
Loading charts...
Drawdowns
LRCX vs. BBIO - Drawdown Comparison
The maximum LRCX drawdown since its inception was -87.90%, smaller than the maximum BBIO drawdown of -92.80%. Use the drawdown chart below to compare losses from any high point for LRCX and BBIO.
Loading charts...
Drawdown Indicators
| LRCX | BBIO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -87.90% | -92.80% | +4.90% |
Max Drawdown (1Y)Largest decline over 1 year | -41.76% | -20.25% | -21.51% |
Max Drawdown (3Y)Largest decline over 3 years | -47.10% | -49.08% | +1.98% |
Max Drawdown (5Y)Largest decline over 5 years | -56.39% | -90.72% | +34.33% |
Max Drawdown (10Y)Largest decline over 10 years | -56.39% | — | — |
Current DrawdownCurrent decline from peak | -32.38% | -11.18% | -21.20% |
Average DrawdownAverage peak-to-trough decline | -28.13% | -45.08% | +16.95% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 9.87% | 9.00% | +0.87% |
Volatility
LRCX vs. BBIO - Volatility Comparison
Lam Research Corporation (LRCX) has a higher volatility of 27.34% compared to BridgeBio Pharma, Inc. (BBIO) at 17.23%. This indicates that LRCX's price experiences larger fluctuations and is considered to be riskier than BBIO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| LRCX | BBIO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 27.34% | 17.23% | +10.11% |
Volatility (6M)Calculated over the trailing 6-month period | 52.39% | 37.06% | +15.33% |
Volatility (1Y)Calculated over the trailing 1-year period | 63.10% | 48.65% | +14.45% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 48.97% | 86.05% | -37.08% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 46.20% | 83.29% | -37.09% |
Dividends
LRCX vs. BBIO - Dividend Comparison
LRCX's dividend yield for the trailing twelve months is around 0.35%, while BBIO has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BBIO BridgeBio Pharma, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
LRCX Lam Research Corporation | 0.35% | 0.57% | 1.19% | 0.95% | 1.53% | 0.78% | 1.04% | 1.54% | 2.79% | 1.01% | 1.28% | 1.36% |
Financials
LRCX vs. BBIO - Financials Comparison
This section allows you to compare key financial metrics between Lam Research Corporation and BridgeBio Pharma, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
LRCX vs. BBIO - Profitability Comparison
LRCX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Lam Research Corporation reported a gross profit of 3.48B and revenue of 6.72B. Therefore, the gross margin over that period was 51.8%.
BBIO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, BridgeBio Pharma, Inc. reported a gross profit of 178.39M and revenue of 180.60M. Therefore, the gross margin over that period was 98.8%.
LRCX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Lam Research Corporation reported an operating income of 2.51B and revenue of 6.72B, resulting in an operating margin of 37.4%.
BBIO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, BridgeBio Pharma, Inc. reported an operating income of -105.96M and revenue of 180.60M, resulting in an operating margin of -58.7%.
LRCX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Lam Research Corporation reported a net income of 2.28B and revenue of 6.72B, resulting in a net margin of 33.9%.
BBIO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, BridgeBio Pharma, Inc. reported a net income of -164.04M and revenue of 180.60M, resulting in a net margin of -90.8%.
Frequently Asked Questions
LRCX and BBIO have a correlation of 0.29, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
LRCX has higher volatility (27.34%) compared to BBIO (17.23%). In terms of maximum drawdown, LRCX dropped -87.90% vs BBIO's -92.80%.
LRCX currently has the higher Sharpe Ratio (3.37 vs 1.44), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for LRCX and BBIO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer